*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Lauren Liebman
BME PhD Proposal Presentation
Date:2022-02-03
Time: 8:30 AM
Location / Meeting Link: IBB Suddath Room, https://bluejeans.com/965751828/9658
Committee Members:
J. Brandon Dixon, PhD (Advisor); Edward Botchwey, PhD; Zachary Buchwald, MD, PhD; Andres Garcia, PhD; Johnna Temenoff, PhD
Title: Investigation of and therapeutic intervention in the crosstalk between inflammation and lymphatic function
Abstract: The lymphatic system is a complex network of lymphatic vessels, lymph nodes, and lymphoid organs responsible for transporting interstitial fluid, lipids, macromolecules, and immune cells. Crosstalk between inflammation and lymphatic function is a hallmark of numerous pathologies, including lymphedema—a disease that often arises following lymphatic damage by cancer treatment. Application of specialized pro-resolving mediators (SPMs) is a potential approach to rescue lymphatic function and attenuate inflammation to treat inflammatory diseases. The proposed work will investigate crosstalk between inflammation and lymphatic function in two murine models: a radiotherapy model for the treatment of melanoma and a surgical model of lymphedema. We will evaluate lymphatic function and remodeling after radiotherapy with and without surgical disruptions of lymphatic vessels in a mouse model of metastatic melanoma (Aim 1). We will also investigate effects of SPM treatment on lymphatic endothelial cells (LECs) and lymphatic muscle cells in multiple in vitro studies: transwell assays to evaluate LEC permeability following treatment and application of our laboratory’s custom three-dimensional spheroid platform to evaluate lymphangiogenic response to treatment (Aim 2). In Aim 3, we will evaluate sustained delivery of SPMs as a therapeutic strategy to resolve lymphatic injury in a surgical mouse tail model of lymphedema. Mice will be injected with SPM-loaded polymeric particles that have been optimized to prolong SPM release. In total, these studies will further our understanding of interactions between inflammation and lymphatic function and will establish a new therapeutic strategy for lymphatic injury.
